...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Angiotensin receptor subtype 1 mediates angiotensin II enhancement of isoproterenol-induced cyclic AMP production in preglomerular microvascular smooth muscle cells.
【24h】

Angiotensin receptor subtype 1 mediates angiotensin II enhancement of isoproterenol-induced cyclic AMP production in preglomerular microvascular smooth muscle cells.

机译:血管紧张素受体亚型1介导血管紧张素II增强肾小球前微血管平滑肌细胞中异丙肾上腺素诱导的环状AMP产生。

获取原文
获取原文并翻译 | 示例
           

摘要

In a previous study, we found that angiotensin (Ang) II enhances beta-adrenoceptor-induced cAMP production in cultured preglomerular microvascular smooth muscle cells (PMVSMCs) obtained from spontaneously hypertensive rats. The purpose of the present investigation was to identify the Ang receptor subtypes that mediate this effect. In our first study, we compared the ability of Ang II, Ang III, Ang (3-8), and Ang (1-7) to increase cAMP production in isoproterenol (1 microM)-treated PMVSMCs. Each peptide was tested at 0.1, 1, 10, 100, and 1000 nM. Both Ang II and Ang III increased intracellular (EC50s, 1 and 11 nM, respectively) and extracellular (EC50s, 2 and 14 nM, respectively) cAMP levels in a concentration-dependent fashion. In contrast, Ang (3-8) and Ang (1-7) did not enhance either intracellular or extracellular cAMP levels at any concentration tested. In our second study, we examined the ability of L 158809 [a selective Ang receptor subtype 1 (AT1) receptor antagonist] to inhibit Ang II (100 nM) and Ang III (100 nM) enhancement of isoproterenol (1 microM)-induced cAMP production in PMVSMCs. L 158809 (10 nM) abolished or nearly abolished (p <.001) Ang II and Ang III enhancement of isoproterenol-induced intracellular and extracellular cAMP levels. In contrast, PD 123319 (300 nM; a selective AT2 receptor antagonist) did not significantly alter Ang II enhancement of isoproterenol-induced intracellular or extracellular cAMP levels. We conclude that AT1 receptors, but not AT2, Ang (3-8), nor Ang (1-7) receptors mediate Ang II and Ang III enhancement of beta-adrenoceptor-induced cAMP production in cultured PMVSMCs.
机译:在先前的研究中,我们发现血管紧张素(Ang)II在自发性高血压大鼠培养的肾小球前微血管平滑肌细胞(PMVSMC)中增强了β-肾上腺素受体诱导的cAMP的产生。本研究的目的是鉴定介导该作用的Ang受体亚型。在我们的第一项研究中,我们比较了Ang II,Ang III,Ang(3-8)和Ang(1-7)提高异丙肾上腺素(1 microM)处理的PMVSMC中cAMP产生的能力。以0.1、1、10、100和1000 nM测试每种肽。 Ang II和Ang III均以浓度依赖的方式增加细胞内(分别为EC50、1和11 nM)和细胞外(分别为EC50、2和14 nM)cAMP水平。相反,在任何测试浓度下,Ang(3-8)和Ang(1-7)均未提高细胞内或细胞外cAMP水平。在我们的第二项研究中,我们研究了L 158809 [选择性Ang受体亚型1(AT1)受体拮抗剂]抑制Ang II(100 nM)和Ang III(100 nM)增强异丙肾上腺素(1 microM)诱导的cAMP的能力。在PMVSMC中生产。 L 158809(10 nM)消除或几乎消除(p <.001)Ang II和Ang III增强了异丙肾上腺素诱导的细胞内和细胞外cAMP水平。相反,PD 123319(300 nM;选择性AT2受体拮抗剂)并未显着改变Ang II对异丙肾上腺素诱导的细胞内或细胞外cAMP水平的增强。我们得出结论,在培养的PMVSMC中,AT1受体而不是AT2,Ang(3-8)或Ang(1-7)受体都不介导Ang II和Ang III增强β-肾上腺素受体诱导的cAMP产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号